Literature DB >> 16699878

Implication of cannabinoids in neurological diseases.

Angela Alsasua del Valle1.   

Abstract

1. Preparations from Cannabis sativa (marijuana) have been used for many centuries both medicinally and recreationally. 2. Recent advances in the knowledge of its pharmacological and chemical properties in the organism, mainly due to Delta(9)-tetrahydrocannabinol, and the physiological roles played by the endocannabinoids have opened up new strategies in the treatment of neurological and psychiatric diseases. 3. Potential therapeutic uses of cannabinoid receptor agonists include the management of spasticity and tremor in multiple sclerosis/spinal cord injury, pain, inflammatory disorders, glaucoma, bronchial asthma, cancer, and vasodilation that accompanies advanced cirrhosis. CB(1) receptor antagonists have therapeutic potential in Parkinson's disease. 4. Dr. Julius Axelrod also contributed in studies on the neuroprotective actions of cannabinoids.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16699878     DOI: 10.1007/s10571-006-9070-8

Source DB:  PubMed          Journal:  Cell Mol Neurobiol        ISSN: 0272-4340            Impact factor:   5.046


  73 in total

1.  Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity.

Authors:  M Shen; S A Thayer
Journal:  Mol Pharmacol       Date:  1998-09       Impact factor: 4.436

Review 2.  Pharmacology of cannabinoid CB1 and CB2 receptors.

Authors:  R G Pertwee
Journal:  Pharmacol Ther       Date:  1997       Impact factor: 12.310

Review 3.  Acute neuronal injury, excitotoxicity, and the endocannabinoid system.

Authors:  Mario van der Stelt; Wouter B Veldhuis; Mauro Maccarrone; Peter R Bär; Klaas Nicolay; Gerrit A Veldink; Vincenzo Di Marzo; Johannes F G Vliegenthart
Journal:  Mol Neurobiol       Date:  2002 Oct-Dec       Impact factor: 5.590

4.  Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study.

Authors:  C B Carroll; P G Bain; L Teare; X Liu; C Joint; C Wroath; S G Parkin; P Fox; D Wright; J Hobart; J P Zajicek
Journal:  Neurology       Date:  2004-10-12       Impact factor: 9.910

Review 5.  Cannabis and the brain.

Authors:  Leslie Iversen
Journal:  Brain       Date:  2003-06       Impact factor: 13.501

6.  Neuroprotection by the cannabinoid agonist WIN-55212 in an in vivo newborn rat model of acute severe asphyxia.

Authors:  José Martínez-Orgado; Beatriz Fernández-Frutos; Rita González; Eva Romero; Leire Urigüen; Julián Romero; M Paz Viveros
Journal:  Brain Res Mol Brain Res       Date:  2003-06-10

Review 7.  The endogenous cannabinoid system and the basal ganglia. biochemical, pharmacological, and therapeutic aspects.

Authors:  Julián Romero; Isabel Lastres-Becker; Rosario de Miguel; Fernando Berrendero; José A Ramos; Javier Fernández-Ruiz
Journal:  Pharmacol Ther       Date:  2002-08       Impact factor: 12.310

8.  The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons.

Authors:  S D Skaper; A Buriani; R Dal Toso; L Petrelli; S Romanello; L Facci; A Leon
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-30       Impact factor: 11.205

9.  Cannabinoids control spasticity and tremor in a multiple sclerosis model.

Authors:  D Baker; G Pryce; J L Croxford; P Brown; R G Pertwee; J W Huffman; L Layward
Journal:  Nature       Date:  2000-03-02       Impact factor: 49.962

10.  Cannabinoids inhibit neurodegeneration in models of multiple sclerosis.

Authors:  Gareth Pryce; Zubair Ahmed; Deborah J R Hankey; Samuel J Jackson; J Ludovic Croxford; Jennifer M Pocock; Catherine Ledent; Axel Petzold; Alan J Thompson; Gavin Giovannoni; M Louise Cuzner; David Baker
Journal:  Brain       Date:  2003-07-22       Impact factor: 13.501

View more
  4 in total

1.  Modulation of inflammatory responses by a cannabinoid-2-selective agonist after spinal cord injury.

Authors:  Sabina Adhikary; Hongbo Li; Joshua Heller; Mario Skarica; Ming Zhang; Doina Ganea; Ronald F Tuma
Journal:  J Neurotrauma       Date:  2011-10-04       Impact factor: 5.269

Review 2.  Roles of transient receptor potential vanilloid subtype 1 and cannabinoid type 1 receptors in the brain: neuroprotection versus neurotoxicity.

Authors:  Sang R Kim; Young C Chung; Eun S Chung; Keun W Park; So Y Won; E Bok; Eun S Park; Byung K Jin
Journal:  Mol Neurobiol       Date:  2007-06       Impact factor: 5.590

Review 3.  Poisonous Plants of the Indian Himalaya: An Overview.

Authors:  Abhishek Jamloki; Vijay Laxmi Trivedi; M C Nautiyal; Prabhakar Semwal; Natália Cruz-Martins
Journal:  Metabolites       Date:  2022-06-13

Review 4.  Cannabinoids in health and disease.

Authors:  Natalya M Kogan; Raphael Mechoulam
Journal:  Dialogues Clin Neurosci       Date:  2007       Impact factor: 5.986

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.